XBiotech Ownership
| XBIT Stock | USD 7.61 0.26 3.54% |
Shares in Circulation | First Issued 2014-03-31 | Previous Quarter 30 M | Current Value 30 M | Avarage Shares Outstanding 31.7 M | Quarterly Volatility 4.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
XBiotech |
XBiotech Stock Ownership Analysis
About 35.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 1.21. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. XBiotech recorded a loss per share of 1.08. The entity last dividend was issued on the 15th of July 2021. XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company was incorporated in 2005 and is headquartered in Austin, Texas. Xbiotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 96 people. For more information please call John Simard at 512 386 2900 or visit https://www.xbiotech.com.Besides selling stocks to institutional investors, XBiotech also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different XBiotech's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align XBiotech's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
XBiotech Quarterly Liabilities And Stockholders Equity |
|
XBiotech Insider Trades History
About 35.0% of XBiotech are currently held by insiders. Unlike XBiotech's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against XBiotech's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of XBiotech's insider trades
XBiotech Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as XBiotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading XBiotech backward and forwards among themselves. XBiotech's institutional investor refers to the entity that pools money to purchase XBiotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 77.7 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 72.5 K | Empowered Funds, Llc | 2024-06-30 | 69.1 K | Charles Schwab Investment Management Inc | 2024-09-30 | 58.4 K | Fmr Inc | 2024-09-30 | 29 K | Nuveen Asset Management, Llc | 2024-06-30 | 24.9 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 23.6 K | Rhumbline Advisers | 2024-06-30 | 20.1 K | Citigroup Inc | 2024-09-30 | 14.5 K | Blackrock Inc | 2024-06-30 | 1.1 M | Vanguard Group Inc | 2024-09-30 | 1.1 M |
XBiotech Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific XBiotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on XBiotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases XBiotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
XBiotech Outstanding Bonds
XBiotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. XBiotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most XBiotech bonds can be classified according to their maturity, which is the date when XBiotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
XBiotech Corporate Filings
10Q | 13th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F4 | 21st of June 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 20th of June 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 1st of May 2024 An amendment to a previously filed Form 10-K | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for XBiotech Stock Analysis
When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.